-
Anteris Technologies director Stephen Denaro resigns from board
-
Anteris Technologies ends supply deal with 4C Medical
-
Anteris Technologies Global (AVR) files for 9.1M share offering by selling stockholders
-
Anteris Technologies begins pivotal trial for heart valve device
-
Anteris receives European clearance for heart valve trial
-
Cantor Fitzgerald Reiterates Overweight Rating on Anteris Technologies Global (AVR)
-
Anteris Technologies Global (AVR) Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR THV
-
Anteris (AVR) Reports One-Year Patient Outcomes for DurAVR THV
-
Cantor Fitzgerald newsletter says Elutia best, Anteris worst performer
-
Cantor Fitzgerald Starts Anteris Technologies Global (AVR) at Overweight
-
TD Cowen Starts Anteris Technologies Global (AVR) at Buy
-
Barclays Starts Anteris Technologies Global (AVR) at Overweight
-
Anteris Technologies Global Corp. (AVR) Announces Launch of U.S. Initial Public Offering
-
Anteris Submits Confidential Draft Registration Statement for Proposed US IPO

